Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017589 · ClinicalTrials.gov registry record · Phase 2
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
A Phase 2 study, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00017589: Completed Phase 2 study, sponsored by Genta Incorporated.
NCT00017589 is a Phase 2 study that has completed, run by Genta Incorporated. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017589, a Phase 2 study, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Oblimersen may help gemtuzumab ozogamicin kill more cancer cells by making cancer cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of combining oblimersen and gemtuzumab ozogamicin in treating older patients who have relapsed acute myeloid leukemia.
Interventions
- DRUG gemtuzumab ozogamicin
- BIOLOGICAL oblimersen sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-12 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
What the finished NCT00017589 record still lists
NCT00017589 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which gemtuzumab ozogamicin is the first listed.
NCT00017589 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00017589 about?
NCT00017589 is a clinical study titled "Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia". RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Oblimersen may help gemtuzumab ozogamicin kill more cancer cells by making cancer cells more sensitive to the drug. PU...
What is the current status of trial NCT00017589?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-12. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00017589?
The interventions under investigation include: gemtuzumab ozogamicin (DRUG), oblimersen sodium (BIOLOGICAL).
Who is sponsoring clinical trial NCT00017589?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia